Evidence map›Paper›PMID 33789384›Full record

ArticleKidney research and clinical practice2021

Histopathologic and clinicopathologic classifications of antineutrophil cytoplasmic antibody-associated glomerulonephritis: a validation study in a Korean cohort.

Jeong-Hoon Lim, Man-Hoon Han, Yong-Jin Kim, Yena Jeon, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Hajeong Lee and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Kidney research and clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jeong-Hoon LimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Man-Hoon HanDepartment of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
Yong-Jin KimDepartment of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
Yena JeonDepartment of Statistics, Kyungpook National University, Daegu, Republic of Korea.
Hee-Yeon JungDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Ji-Young ChoiDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Jang-Hee ChoDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Chan-Duck KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Yong-Lim KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Hajeong LeeDepartment of Internal Medicine, Seoul National University School of Medicine, Seoul, Republic of Korea.
Dong Ki KimDepartment of Internal Medicine, Seoul National University School of Medicine, Seoul, Republic of Korea.
Kyung Chul MoonDepartment of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Sun-Hee ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Kyungpook National University Hospital · KRSeoul National University · KRKyungpook National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntineutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis (AAGN) is a common cause of rapidly progressive glomerulonephritis and requires prompt and proper immunosuppressive therapy to improve renal prognosis. This study aimed to evaluate the predictive value of two different classifications for renal outcomes in Korean AAGN patients.

methodsNinety-two patients who were diagnosed with AAGN at two tertiary hospitals between 2004 and 2018 were retrospectively analyzed retrospectively. The histopathologic classification according to glomerular pathology and the clinicopathologic classification according to normal glomeruli ratio, degree of interstitial fibrosis/tubular atrophy, and baseline renal function were evaluated using the Cox proportional hazards model.

resultsForty-five patients (48.9%) progressed to end-stage kidney disease (ESKD) during the observation period. The mean age was 61.0 ± 15.3 years, and most patients had myeloperoxidase-ANCA (93.5%). In the histopathologic classification, the best renal survival occurred in the focal class, whereas the sclerotic class had the worst renal survival (sclerotic class vs. focal class; adjusted hazard ratio [aHR], 5.05; 95% confidence interval [CI], 1.32-19.31; p = 0.018). The mixed class had intermediate renal outcomes (mixed class vs. focal class; aHR, 4.23; 95% CI, 1.23-14.58; p = 0.022). In the clinicopathologic classification, the high-risk group had poor renal outcomes compared with the low-risk group (aHR, 6.56; 95% CI, 1.25-34.26; p = 0.026), but renal outcomes did not differ between the low- and medium-risk groups.

conclusionIn Korean AAGN patients, histopathologic and clinicopathologic classifications had predictive value for renal outcomes, especially in the sclerotic class or the high-risk group with higher risk of progression to ESRD despite treatment.

Indexed as

Antineutrophil cytoplasmic antibody-associated glomerulonephritisClinicopathologic classificationEnd-stage kidney diseaseHistopathologic classification

Identifiers

PMID33789384
PMCPMC8041633
OpenAlexW3134384911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.